search
Back to results

Randomized Placebo-controlled Study of L. Reuteri NCIMB 30351 in GI Functional Disorders and Food Allergy in Newborns

Primary Purpose

Infantile Colic, Constipation, Infantile Diarrhea

Status
Completed
Phase
Not Applicable
Locations
Russian Federation
Study Type
Interventional
Intervention
Lactobacillus Reuteri
Placebo
Sponsored by
NovoNatum Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infantile Colic

Eligibility Criteria

1 Month - 5 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Parents / guardians speak Russian, understand the essence of study, are informed about the purpose of the study, understand their rights and signed informed consent form (ICF).
  2. Vaginal delivery.
  3. Full-term newborn.
  4. Age at the time of the signing of informed consent form 1-4 months 28 days.
  5. Breast- and formula-fed infants.
  6. Colic , constipation , diarrhea, regurgitation (single symptom or combination of several symptoms).
  7. Infant does not have other deviations in health, which would require the appointment of a specialized diet
  8. Parents / guardians can and ready to regularly fill out the proposed diary form.

Exclusion Criteria:

  1. Born by Cesarean section.
  2. Premature newborn.
  3. Congenital abnormalities or other clinical manifestations that may interfere with the study.
  4. Lactase food supplements.
  5. Other probiotic drugs, antibiotics, enteric antiseptics, antifungal and antiprotozoal drugs.

Sites / Locations

  • Children's City Clinical Hospital named after Bashlyaeva, Healthcare department of Moscow city
  • Medical Center "St. Andrew's Hospitals - NEBOLIT"

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Treatment

Control

Arm Description

Outcomes

Primary Outcome Measures

Change in the number of infantile colics
Infantile colics are defined according to IV Rome criteria

Secondary Outcome Measures

Change in the number of constipations
Constipation is defined according to IV Rome criteria
Change in the number of diarrhea cases
Diarrhea is defined according to IV Rome criteria
Change in the number of gastroesophageal reflux (posseting) cases
Gastroesophageal reflux is defined according to IV Rome criteria
Presence of skin symptoms of food allergy
Presence or absence of skin symptoms of food allergy will be assessed by investigator during general skin examination
Change in 16S RNA sequencing
16S RNA in stool
Change in concentrations of stool carbohydrates
Carbohydrates concentrations will be measured in stool filtrate
Change in concentrations in stool filtrate of volatile fatty acids
Following volatile fatty acids concentrations will be assessed: acetic, propionic, butyric, valeric, caproic and their isomers

Full Information

First Posted
February 7, 2020
Last Updated
May 10, 2023
Sponsor
NovoNatum Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT04262648
Brief Title
Randomized Placebo-controlled Study of L. Reuteri NCIMB 30351 in GI Functional Disorders and Food Allergy in Newborns
Official Title
Randomized, Blinded, Placebo-controlled, Study of Clinical and Laboratory Effects of L. Reuteri NCIMB 30351 in Functional Disorders of Gastrointestinal Tract and Skin Symptoms of Food Allergy in Children During the First Months of Life
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
March 3, 2020 (Actual)
Primary Completion Date
May 16, 2022 (Actual)
Study Completion Date
May 16, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NovoNatum Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is a randomized, placebo-controlled, single-masked (blinded), post-marketing clinical study of a drug Lactobacillus Reuteri NCIMB 30351 drops in functional disorders of gastrointestinal tract and skin symptoms of food allergies in children between the ages of one and four months inclusive. The aim of the study is to assess clinical effects of probiotics Lactobacillus Reuteri NCIMB 30351 drops on the symptoms of infantile colic, constipation, diarrhea, gastroesophageal reflux, atopic dermatitis/eczema in full-term newborns during the first months of life, laboratory parameters of microbiome will also be assessed. A prospective study comparing two treatment groups: Group 1 (treatment group) - 60 infants. Group 2 (control group) - 30 infants, placebo. The study drug will be taken in 1 time per day within 25 days. Allowed symptomatic therapy includes defoamers (simethicone-based preparations), carminative preparations (dill water (fennel)), etc.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infantile Colic, Constipation, Infantile Diarrhea, Gastro Esophageal Reflux

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
90 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment
Arm Type
Experimental
Arm Title
Control
Arm Type
Placebo Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
Lactobacillus Reuteri
Other Intervention Name(s)
BioAmicus Lactobacillus drops
Intervention Description
Lactobacillus Reuteri NCIMB 30351
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Sunflower oil
Primary Outcome Measure Information:
Title
Change in the number of infantile colics
Description
Infantile colics are defined according to IV Rome criteria
Time Frame
25 days from the start of treatment
Secondary Outcome Measure Information:
Title
Change in the number of constipations
Description
Constipation is defined according to IV Rome criteria
Time Frame
25 days from the start of treatment
Title
Change in the number of diarrhea cases
Description
Diarrhea is defined according to IV Rome criteria
Time Frame
25 days from the start of treatment
Title
Change in the number of gastroesophageal reflux (posseting) cases
Description
Gastroesophageal reflux is defined according to IV Rome criteria
Time Frame
25 days from the start of treatment
Title
Presence of skin symptoms of food allergy
Description
Presence or absence of skin symptoms of food allergy will be assessed by investigator during general skin examination
Time Frame
25 days from the start of treatment
Title
Change in 16S RNA sequencing
Description
16S RNA in stool
Time Frame
25 days from the start of treatment
Title
Change in concentrations of stool carbohydrates
Description
Carbohydrates concentrations will be measured in stool filtrate
Time Frame
25 days from the start of treatment
Title
Change in concentrations in stool filtrate of volatile fatty acids
Description
Following volatile fatty acids concentrations will be assessed: acetic, propionic, butyric, valeric, caproic and their isomers
Time Frame
25 days from the start of treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Month
Maximum Age & Unit of Time
5 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Parents / guardians speak Russian, understand the essence of study, are informed about the purpose of the study, understand their rights and signed informed consent form (ICF). Vaginal delivery. Full-term newborn. Age at the time of the signing of informed consent form 1-4 months 28 days. Breast- and formula-fed infants. Colic , constipation , diarrhea, regurgitation (single symptom or combination of several symptoms). Infant does not have other deviations in health, which would require the appointment of a specialized diet Parents / guardians can and ready to regularly fill out the proposed diary form. Exclusion Criteria: Born by Cesarean section. Premature newborn. Congenital abnormalities or other clinical manifestations that may interfere with the study. Lactase food supplements. Other probiotic drugs, antibiotics, enteric antiseptics, antifungal and antiprotozoal drugs.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Oleg Tyrsin
Organizational Affiliation
NovoNatum CEO
Official's Role
Study Director
Facility Information:
Facility Name
Children's City Clinical Hospital named after Bashlyaeva, Healthcare department of Moscow city
City
Moscow
Country
Russian Federation
Facility Name
Medical Center "St. Andrew's Hospitals - NEBOLIT"
City
Moscow
Country
Russian Federation

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Randomized Placebo-controlled Study of L. Reuteri NCIMB 30351 in GI Functional Disorders and Food Allergy in Newborns

We'll reach out to this number within 24 hrs